JP2006511555A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006511555A5 JP2006511555A5 JP2004560858A JP2004560858A JP2006511555A5 JP 2006511555 A5 JP2006511555 A5 JP 2006511555A5 JP 2004560858 A JP2004560858 A JP 2004560858A JP 2004560858 A JP2004560858 A JP 2004560858A JP 2006511555 A5 JP2006511555 A5 JP 2006511555A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally
- substituted
- optionally substituted
- aryl
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003118 aryl group Chemical group 0.000 claims 14
- 229920006395 saturated elastomer Polymers 0.000 claims 14
- 229910052757 nitrogen Chemical group 0.000 claims 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 9
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 8
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 239000001301 oxygen Substances 0.000 claims 8
- 229910052698 phosphorus Inorganic materials 0.000 claims 8
- 239000011574 phosphorus Chemical group 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 7
- 125000000304 alkynyl group Chemical group 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 239000011593 sulfur Chemical group 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 241000607479 Yersinia pestis Species 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 238000002651 drug therapy Methods 0.000 claims 2
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 2
- -1 methylenedioxy, ethylenedioxy Chemical group 0.000 claims 2
- 125000003003 spiro group Chemical group 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003178 Arterial thrombosis Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000022461 Glomerular disease Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000009608 Papillomavirus Infections Diseases 0.000 claims 1
- 206010035148 Plague Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 230000000762 glandular Effects 0.000 claims 1
- 231100000852 glomerular disease Toxicity 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 208000021145 human papilloma virus infection Diseases 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000008595 infiltration Effects 0.000 claims 1
- 238000001764 infiltration Methods 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 231100000637 nephrotoxin Toxicity 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43341002P | 2002-12-13 | 2002-12-13 | |
| PCT/US2003/039740 WO2004055011A1 (en) | 2002-12-13 | 2003-12-12 | Heterocyclic compounds as ccr5 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006511555A JP2006511555A (ja) | 2006-04-06 |
| JP2006511555A5 true JP2006511555A5 (enExample) | 2007-01-11 |
Family
ID=32595182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004560858A Pending JP2006511555A (ja) | 2002-12-13 | 2003-12-12 | Ｃｃｒ５拮抗剤としての複素環式化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7452992B2 (enExample) |
| EP (1) | EP1569931B1 (enExample) |
| JP (1) | JP2006511555A (enExample) |
| AT (1) | ATE410426T1 (enExample) |
| AU (1) | AU2003300911A1 (enExample) |
| DE (1) | DE60324014D1 (enExample) |
| ES (1) | ES2312856T3 (enExample) |
| WO (1) | WO2004055011A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004054581A2 (en) * | 2002-12-13 | 2004-07-01 | Smithkline Beecham Corporation | Cyclohexyl compounds as ccr5 antagonists |
| WO2008030853A2 (en) * | 2006-09-06 | 2008-03-13 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
| CN104530048B (zh) | 2008-08-11 | 2016-09-14 | 葛兰素史密丝克莱恩有限责任公司 | 腺嘌呤衍生物 |
| UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| JP2011530562A (ja) | 2008-08-11 | 2011-12-22 | グラクソスミスクライン エルエルシー | アレルギー性、炎症性及び感染性疾患治療用のプリン誘導体 |
| ES2564457T3 (es) * | 2009-07-24 | 2016-03-22 | Glaxosmithkline Llc | Derivados de azabiciclo[3,2,1]octilo para su uso en el tratamiento de VIH |
| CA2786973C (en) | 2010-02-10 | 2018-04-10 | Robert Hermann Gibbon | 6-amino-2-{[(1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate |
| JP2013519644A (ja) | 2010-02-10 | 2013-05-30 | グラクソスミスクライン エルエルシー | プリン誘導体およびそれらの薬学的使用 |
| JO3387B1 (ar) | 2011-12-16 | 2019-03-13 | Glaxosmithkline Llc | مشتقات بيتولين |
| CN106029668B (zh) | 2014-02-20 | 2018-02-23 | 葛兰素史克知识产权第二有限公司 | 吡咯并[3,2]嘧啶衍生物作为人类干扰素诱导剂 |
| MX2017006302A (es) | 2014-11-13 | 2018-02-16 | Glaxosmithkline Biologicals Sa | Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias. |
| CR20180286A (es) | 2015-12-03 | 2018-07-16 | Glaxosmithkline Ip Dev Ltd | Dinucleotidos de purina cíclicos como moduladores de sting |
| US10239847B1 (en) | 2016-03-03 | 2019-03-26 | Cellactin | Method for 2-oxothiazolidine-4-carboxylic acid for cellular glutathione |
| SI3440076T1 (sl) | 2016-04-07 | 2022-09-30 | Glaxosmithkline Intellectual Property Development Limited | Heterociklični amidi uporabni kot proteinski modulatorji |
| BR112018070602A2 (pt) | 2016-04-07 | 2019-02-05 | Glaxosmithkline Ip Dev Ltd | composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio |
| JP7291130B2 (ja) | 2017-10-05 | 2023-06-14 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | インターフェロン遺伝子の刺激物質（ｓｔｉｎｇ）の調節物質 |
| TW201927771A (zh) | 2017-10-05 | 2019-07-16 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 可作為蛋白質調節劑之雜環醯胺及其使用方法 |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| CN109593089B (zh) * | 2019-01-24 | 2022-01-28 | 西南大学 | 二氮杂螺癸烷哌啶甲酰胺类化合物制备和应用 |
| JP2022533194A (ja) | 2019-05-16 | 2022-07-21 | スティングセラ インコーポレイテッド | ベンゾ［ｂ］［１，８］ナフチリジン酢酸誘導体および使用方法 |
| EP3969438A1 (en) | 2019-05-16 | 2022-03-23 | Stingthera, Inc. | Oxoacridinyl acetic acid derivatives and methods of use |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| AU2020409429A1 (en) | 2019-12-18 | 2022-06-16 | Ctxt Pty Ltd | Compounds |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6431570A (en) * | 1987-07-27 | 1989-02-01 | Matsubara Kk | Sand bold transfer type casting method |
| FR2729954B1 (fr) * | 1995-01-30 | 1997-08-01 | Sanofi Sa | Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
| FR2791346B3 (fr) * | 1999-03-25 | 2001-04-27 | Sanofi Sa | Nouveaux derives de morpholine, procede pour leur preparation et compositions pharmaceutiques les contenant |
| WO2002005819A1 (en) * | 2000-07-15 | 2002-01-24 | Smithkline Beecham Corporation | Compounds and methods |
| DK1373256T3 (da) * | 2001-03-29 | 2005-10-10 | Schering Corp | CCR5-antagonister, der er nyttige til behandling af AIDS |
| GB0108876D0 (en) * | 2001-04-09 | 2001-05-30 | Novartis Ag | Organic Compounds |
| FR2824828B1 (fr) * | 2001-05-21 | 2005-05-20 | Sanofi Synthelabo | Nouveaux derives de piperidinecarboxamide, un procede pour leur preparation et les compositions pharmaceutiques les contenant |
-
2003
- 2003-12-12 DE DE60324014T patent/DE60324014D1/de not_active Expired - Lifetime
- 2003-12-12 WO PCT/US2003/039740 patent/WO2004055011A1/en not_active Ceased
- 2003-12-12 AU AU2003300911A patent/AU2003300911A1/en not_active Abandoned
- 2003-12-12 AT AT03813436T patent/ATE410426T1/de not_active IP Right Cessation
- 2003-12-12 JP JP2004560858A patent/JP2006511555A/ja active Pending
- 2003-12-12 US US10/538,145 patent/US7452992B2/en not_active Expired - Fee Related
- 2003-12-12 EP EP03813436A patent/EP1569931B1/en not_active Expired - Lifetime
- 2003-12-12 ES ES03813436T patent/ES2312856T3/es not_active Expired - Lifetime
-
2008
- 2008-10-15 US US12/251,639 patent/US20090053172A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006511555A5 (enExample) | ||
| JP2006514950A5 (enExample) | ||
| JP2006512339A5 (enExample) | ||
| JP2006511552A5 (enExample) | ||
| CN111315737B (zh) | 经砜吡啶烷基酰胺取代的杂芳基化合物 | |
| JP2020537657A5 (enExample) | ||
| RU2003103291A (ru) | Ингибиторы медьсодержащих аминооксидаз | |
| JP5667684B2 (ja) | 関節炎の治療方法 | |
| RU2003105885A (ru) | Ингибиторы клеточной адгезии, опосредованной альфа 4-интегринами | |
| JP2020528889A5 (enExample) | ||
| IL273769B2 (en) | Chemical compounds | |
| JP2020514318A5 (enExample) | ||
| JP2011523412A5 (enExample) | ||
| JP2017510643A5 (enExample) | ||
| MY149978A (en) | Heterocyclic aspartyl protease inhibitors | |
| RU2006105716A (ru) | Производные пиридазина и их применение в качестве терапевтических средств | |
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| RU2002131887A (ru) | Замещенные в орто-положении амиды антраниловой кислоты и их применение в качестве лекарственных средств | |
| RU2016150326A (ru) | Производные изоиндолина для применения в лечении вирусной инфекции | |
| JP2011500621A5 (enExample) | ||
| JP2017502092A5 (enExample) | ||
| JP2020500866A5 (enExample) | ||
| RU99112569A (ru) | Бициклические арильные карбоксамиды и их терапевтическое применение | |
| DK1583538T3 (da) | Anvendelse af 3-methozy-pregnenolon til fremstilling af et lægemiddel til behandling af neurodegenerative sygdomme | |
| JP2014504648A5 (enExample) |